Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients L852.
Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) FDA Label. Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic material into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B A19643. By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as voxilaprevir.
Voxilaprevir has been available since July 2017 in a fixed dose combination product with sofosbuvir and velpatasvir as the commercially available product Vosevi. Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection FDA Label. Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor L935. Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Voxilaprevir. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Voxilaprevir. |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Voxilaprevir. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Voxilaprevir. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Voxilaprevir. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Voxilaprevir. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Voxilaprevir. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Voxilaprevir. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Voxilaprevir. |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Voxilaprevir. |
| Silodosin | The excretion of Silodosin can be decreased when combined with Voxilaprevir. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Voxilaprevir. |
| Deferasirox | The serum concentration of Voxilaprevir can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Voxilaprevir can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Voxilaprevir can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Voxilaprevir can be decreased when it is combined with Teriflunomide. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Voxilaprevir. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Voxilaprevir. |
| Mifepristone | The serum concentration of Voxilaprevir can be increased when it is combined with Mifepristone. |
| Abiraterone | The serum concentration of Voxilaprevir can be increased when it is combined with Abiraterone. |
| Eluxadoline | The serum concentration of Eluxadoline can be increased when it is combined with Voxilaprevir. |
| Vincristine | The excretion of Vincristine can be decreased when combined with Voxilaprevir. |
| Cyproterone acetate | The metabolism of Voxilaprevir can be increased when combined with Cyproterone acetate. |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Voxilaprevir. |
| Lumacaftor | The serum concentration of Voxilaprevir can be decreased when it is combined with Lumacaftor. |
| Primidone | The metabolism of Voxilaprevir can be increased when combined with Primidone. |
| Rifampin | The metabolism of Voxilaprevir can be increased when combined with Rifampicin. |
| Carbamazepine | The metabolism of Voxilaprevir can be increased when combined with Carbamazepine. |
| Albendazole | The metabolism of Voxilaprevir can be increased when combined with Albendazole. |
| Caffeine | The metabolism of Voxilaprevir can be decreased when combined with Caffeine. |
| Moxifloxacin | The metabolism of Voxilaprevir can be decreased when combined with Moxifloxacin. |
| Mexiletine | The metabolism of Voxilaprevir can be decreased when combined with Mexiletine. |
| Alosetron | The metabolism of Voxilaprevir can be decreased when combined with Alosetron. |
| Gatifloxacin | The metabolism of Voxilaprevir can be decreased when combined with Gatifloxacin. |
| Simeprevir | The metabolism of Voxilaprevir can be decreased when combined with Simeprevir. |
| Lobeglitazone | The metabolism of Voxilaprevir can be decreased when combined with Lobeglitazone. |
| Pazufloxacin | The metabolism of Voxilaprevir can be decreased when combined with Pazufloxacin. |
| Lidocaine | The metabolism of Voxilaprevir can be decreased when combined with Lidocaine. |
| Osilodrostat | The metabolism of Voxilaprevir can be decreased when combined with Osilodrostat. |
| Secobarbital | The metabolism of Voxilaprevir can be increased when combined with Secobarbital. |
| Phenobarbital | The metabolism of Voxilaprevir can be increased when combined with Phenobarbital. |
| Bexarotene | The metabolism of Voxilaprevir can be decreased when combined with Bexarotene. |
| Diltiazem | The metabolism of Voxilaprevir can be decreased when combined with Diltiazem. |
| Medroxyprogesterone acetate | The metabolism of Voxilaprevir can be decreased when combined with Medroxyprogesterone acetate. |
| Nicardipine | The metabolism of Voxilaprevir can be decreased when combined with Nicardipine. |
| Irbesartan | The metabolism of Voxilaprevir can be decreased when combined with Irbesartan. |
| Oxybutynin | The metabolism of Voxilaprevir can be decreased when combined with Oxybutynin. |
| Fluvastatin | The metabolism of Voxilaprevir can be decreased when combined with Fluvastatin. |
| Pioglitazone | The metabolism of Voxilaprevir can be decreased when combined with Pioglitazone. |
| Levothyroxine | The metabolism of Voxilaprevir can be decreased when combined with Levothyroxine. |
| Loratadine | The metabolism of Voxilaprevir can be decreased when combined with Loratadine. |
| Trimethoprim | The metabolism of Voxilaprevir can be decreased when combined with Trimethoprim. |
| Fluticasone propionate | The metabolism of Voxilaprevir can be decreased when combined with Fluticasone propionate. |
| Clopidogrel | The metabolism of Voxilaprevir can be decreased when combined with Clopidogrel. |
| Candesartan cilexetil | The metabolism of Voxilaprevir can be decreased when combined with Candesartan cilexetil. |
| Salmeterol | The metabolism of Voxilaprevir can be decreased when combined with Salmeterol. |
| Gemfibrozil | The metabolism of Voxilaprevir can be decreased when combined with Gemfibrozil. |
| Fluticasone | The metabolism of Voxilaprevir can be decreased when combined with Fluticasone. |
| Mometasone furoate | The metabolism of Voxilaprevir can be decreased when combined with Mometasone furoate. |
| Felodipine | The metabolism of Voxilaprevir can be decreased when combined with Felodipine. |
| Osimertinib | The serum concentration of Voxilaprevir can be decreased when it is combined with Osimertinib. |
| Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Voxilaprevir. |
| Vemurafenib | The serum concentration of Voxilaprevir can be increased when it is combined with Vemurafenib. |
| Apalutamide | The serum concentration of Voxilaprevir can be decreased when it is combined with Apalutamide. |
| Pitolisant | The serum concentration of Voxilaprevir can be decreased when it is combined with Pitolisant. |
| Isavuconazole | The serum concentration of Voxilaprevir can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Voxilaprevir can be increased when it is combined with Isavuconazonium. |
| Imatinib | Imatinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Sulfasalazine | Sulfasalazine may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Novobiocin | Novobiocin may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Hesperetin | Hesperetin may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Rabeprazole | Rabeprazole may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Genistein | The metabolism of Voxilaprevir can be decreased when combined with Genistein. |
| Topiroxostat | The metabolism of Voxilaprevir can be decreased when combined with Topiroxostat. |
| Daidzin | Daidzin may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Fusidic acid | The metabolism of Voxilaprevir can be decreased when combined with Fusidic acid. |
| Naringenin | Naringenin may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Vandetanib | Vandetanib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Eltrombopag | The metabolism of Voxilaprevir can be decreased when combined with Eltrombopag. |
| Safinamide | Safinamide may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Cannabidiol | Cannabidiol may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Palbociclib | Palbociclib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Glasdegib | Glasdegib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Fostamatinib | Fostamatinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Folic acid | Voxilaprevir may decrease the excretion rate of Folic acid which could result in a higher serum level. |
| Allopurinol | Voxilaprevir may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
| Celecoxib | Voxilaprevir may decrease the excretion rate of Celecoxib which could result in a higher serum level. |
| Oxaliplatin | Voxilaprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. |
| Methotrexate | Voxilaprevir may decrease the excretion rate of Methotrexate which could result in a higher serum level. |
| Clofarabine | Voxilaprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Tamoxifen | The metabolism of Voxilaprevir can be decreased when combined with Tamoxifen. |
| Nitrofurantoin | Voxilaprevir may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Riluzole | Voxilaprevir may decrease the excretion rate of Riluzole which could result in a higher serum level. |
| Rosuvastatin | Voxilaprevir may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. |
| Alvocidib | Voxilaprevir may decrease the excretion rate of Alvocidib which could result in a higher serum level. |
| Riociguat | Voxilaprevir may decrease the excretion rate of Riociguat which could result in a higher serum level. |
| Lenvatinib | Voxilaprevir may decrease the excretion rate of Lenvatinib which could result in a higher serum level. |
| Fimasartan | Voxilaprevir may decrease the excretion rate of Fimasartan which could result in a higher serum level. |
| Delafloxacin | Voxilaprevir may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
| Gilteritinib | Gilteritinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |